Professor Camilla Krakstad has her background from research on signal transduction, and during her PhD she studied cAMP signaling in apoptotic cell death in both normal and cancer cells.
She is also well trained in the use of animal models in medical research and was involved in development and characterization of a mouse knock out model for the cAMP receptor EPAC. In 2010 she joined the translational research team focusing on gynecologic cancers, previously headed by Helga B. Salvesen. Combining her background from signal transduction with valuable patient samples inspired more clinical focused research with a particular interest in improving treatment of endometrial cancer patients.
Krakstad has been involved in the identification and validation of several potent biomarkers for endometrial cancer, among others several members of the hormone receptor family have been studied (Br J Cancer 2012, E J Cancer 2015, Oncotraget 2016). The team has pointed to important molecular alterations underlying development of aggressive, hormone receptor negative disease and will further explore these observations in preclinical model systems, including both cell and animal models.
State-of-the-art animal models and advanced molecular imaging of endometrial cancer has been established (PlosOne 2015). These models are currently used for drug testing and validation of predictive value of specific biomarkers. As an example, the biomarker Stathmin is currently being tested as a predictive biomarker for drug response based on previous work. Drug testing in mouse models is also part of a strong collaboration with Professor Ingfrid Haldorsen to identify functional imaging parameters of tumors in patients and mice related to clinically relevant biomarkers.
In ongoing and future projects, the group will continue to combine genetic and molecular studies of precursor, primary and metastatic lesions with registry data to identify new biomarkers and further define the development and progression of gynecologic cancers. The group’s findings in experimental cell and animal models will be further explored. The future goal is that novel potential targets and biomarkers will be validated in the human setting through collaborations with both local (CCBIO) and international partners.